Stay updated with breaking news from Mdgl. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) has earned an average rating of “Moderate Buy” from the seven research firms that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average 1-year price objective […] ....
Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) have been given an average recommendation of “Moderate Buy” by the seven research firms that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The […] ....
JMP Securities reissued their market outperform rating on shares of Madrigal Pharmaceuticals (NASDAQ:MDGL – Free Report) in a report published on Friday, Benzinga reports. They currently have a $347.00 price objective on the biopharmaceutical company’s stock. Several other equities research analysts have also issued reports on MDGL. StockNews.com upgraded Madrigal Pharmaceuticals to a sell rating […] ....
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) – Equities research analysts at Leerink Partnrs issued their Q1 2024 earnings per share estimates for shares of Madrigal Pharmaceuticals in a research note issued on Monday, February 5th. Leerink Partnrs analyst T. Smith forecasts that the biopharmaceutical company will post earnings per share of ($5.11) for the […] ....
New clinical trial results from El Lilly suggest its Type 2 diabetes and weight-loss drug, tirzepatide, could upend the incipient market for MASH treatments. ....